The immunogenicity of insulin preparations
- PMID: 793278
The immunogenicity of insulin preparations
Abstract
Patients who had never received insulin were administered porcine or bovine Lente insulins prepared from either conventional USP-grade insulin, "single-peak" insulin (SPI), or "single-component" insulin (SCI) in an attempt to determine if insulin immunogenecity was related to the purity of various insulin preparations. Serum insulin antibody titers were monitored by a sensitive I125-insulin binding procedure. All six groups of patients had some degree of antibody formation after six months of continuous insulin administration. Based upon the percent of I125-insulin bound by the serum, the least immunogenic insulin preparation was the porcine SCI. The most immunogenic insulins were the bovine preparations, all three of which gave comparable antibody responses. The patients who received porcine USP insulin and porcine SPI had similar antibody titers, both of which were significantly higher than the titers from the patients on porcine SCI, but significantly lower than the antibody titers from the patients treated with any of the bovine preparations. The immunogenicity of bovine SCI was significantly reduced by administering multiple daily doses of the neutral regular form instead of one or two daily injections of the Lente form, Although these purer insulin preparations (SPI and SCI) are still associated with various degrees of immunogenecity, they are significant improvements for the treatment of insulin lipoatrophy and insulin allergy.
Similar articles
-
[Purity and antigenicity of the new insulin preparations].Schweiz Med Wochenschr. 1976 Sep 4;106(36):1218-25. Schweiz Med Wochenschr. 1976. PMID: 996531 German.
-
Insulin antibodies in diabetics receiving a single type of insulin.Med Interne. 1982 Jan-Mar;20(1):9-13. Med Interne. 1982. PMID: 6765628
-
Behaviour of insulin antibodies in diabetics treated with different insulins.Med Interne. 1980 Oct-Dec;18(4):347-52. Med Interne. 1980. PMID: 7006044
-
Immunogenicity and allergenic potential of animal and human insulins.Diabetes Care. 1993 Dec;16 Suppl 3:155-65. doi: 10.2337/diacare.16.3.155. Diabetes Care. 1993. PMID: 8299472 Review.
-
The immunogenicity of new insulins.Diabetes. 1985 Jun;34 Suppl 2:94-6. doi: 10.2337/diab.34.2.s94. Diabetes. 1985. PMID: 3888748 Review.
Cited by
-
Pancreatic polypeptide.J Clin Pathol Suppl (Assoc Clin Pathol). 1978;8:43-50. doi: 10.1136/jcp.s1-8.1.43. J Clin Pathol Suppl (Assoc Clin Pathol). 1978. PMID: 298737 Free PMC article. No abstract available.
-
New insulins: their role in the treatment of diabetes.Drugs. 1979 Apr;17(4):289-96. doi: 10.2165/00003495-197917040-00003. Drugs. 1979. PMID: 456293 No abstract available.
-
Insulin binding capacity in patients changed from conventional to highly purified insulins. An indicator of likely response.Diabetologia. 1977 Aug;13(4):311-5. doi: 10.1007/BF01223271. Diabetologia. 1977. PMID: 562300
-
Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin.Diabetologia. 1980;18(2):147-50. doi: 10.1007/BF00290492. Diabetologia. 1980. PMID: 6988274
-
Characterization of proinsulin-insulin intermediates in human plasma.J Clin Invest. 1978 Oct;62(4):727-37. doi: 10.1172/JCI109183. J Clin Invest. 1978. PMID: 359597 Free PMC article.